New PSP for Lorlatinib in 2nd line ALK translocated - Amivantamab + Lazertinib in first line mEGFR - Amivantamab + CT in second line EGFR post Osimertinib -

Update 5 October 2025

Tepotinib

Lung – NSCLC / Metastatic

Québec / Canada

11 mos.

positive 28 May 2020

Clinical Trials

15 mos.

positive 27 May 2021

Health Canada

9 mos.

positive 31 August 2022

INESSS (QC)

negative 24 August 2022

pCODR (CA)

14 days.

positive 22 June 2023

pCPA

positive 6 July 2023

RAMQ / LM

Comparison with other countries

United States

United States

3 mos.

positive 3 February 2021

FDA approval

Canada

Canada

8 mos.

positive 27 May 2021

Health Canada

Europe

Europe

positive 16 February 2022

EMA approval

Tepotinib was previously granted accelerated approval by the FDA for this indication on February 3, 2021, based on ORR and DOR in the VISION trial. They were granted traditional approval on February 15, 2024.

It is fully funded and available for patients in Quebec, but unfortunately a negative recommendation from pCODR.

For patients covered by the Quebec’s Health Insurance Plan / RAMQ, please fill out the form directly on the RAMQ website and submit it for approval.

Private Insurance

For patients with a personal health insurance, search for the drug (using sometimes its commercial name) download and fill out the appropriate prior authorization form. If you are unable to find the drug, you should fill out the General Form available on the same page (contact me if you have trouble locating it).
Manulife and Sunlife have a more complicated way, links will download a detailed pdf, please open it and follow the instructions :

Patient Support Program

Log in to the portal to access the Patient Support Program document.

Create an account

"*" indicates required fields

First name*

Last name*

Email*

Only institutional emails will be accepted

Permit number*

Username*

Password*

Enter Password Confirm Password

Strength indicator

Les renseignements ci-dessus [ou « ci-dessous »], c’est-à-dire collectés via ce formulaire nous sont nécessaires à la création de votre compte et pour vous permettre d’accéder à notre portail. Ils sont exclusivement destinés à être traités par les seuls employés de Howitreat qui doivent y avoir accès dans le cadre de l’exercice de leur fonction, ainsi qu’à ses sous-traitants éventuels pour des raisons exclusivement techniques et logistiques, et à ses partenaires notamment [le cas échéant, insérer le nom du partenaire et la finalité recherchée]. Les renseignements sont stockés sur nos serveurs, situés au Canada, et des mesures de sécurité physiques, organisationnelles, contractuelles et technologiques dans le but de les protéger ont été mises en place. Nous utiliserons, divulguerons ou conserverons ces enregistrements uniquement le temps nécessaire à la réalisation des objectifs poursuivis et dans la mesure permise ou requise par la loi. Vous disposez d’un droit d’accès et de rectification à l’égard de vos renseignements personnels et vous pouvez retirer votre consentement à tout moment. Pour toutes les questions que vous pourriez avoir, vous pouvez contacter notre Responsable à la protection des renseignements personnels aux coordonnées indiquées dans notre politique de confidentialité. Pour en savoir plus, cliquez ici: Politique de confidentialité

CAPTCHA

Connection

Disclaimer

We do not provide medical or professional advice.

Howitreat (the “Site” or “We”) provides the public and healthcare professionals with information about various types of cancers, their origins, available treatments, and helps optimize the internal logistics for healthcare professionals. It is designed to serve informational purposes and reflects my approach to practice. The Site should not be used as a replacement for a healthcare professional’s professional opinion, and should only be used to supplement standard medical practices. While we strive to provide accurate and up-to-date information, we cannot guarantee its completeness or timeliness. The Site may contain links to external websites or resources that are not controlled or maintained by us. We do not endorse or assume any responsibility for the content, accuracy, or availability of these external sites. The information provided through the Site is not a substitute for medical advice, and you should not rely on it for medical diagnosis, assessment, or treatment. We do not endorse or recommend any specific products or treatments mentioned on the Site. Your reliance on any information provided by us or available on the Site is at your own risk.

Always consult with your physician (or another qualified healthcare professional) for any questions or concerns regarding your personal health, medical conditions, medications, and before initiating or discontinuing any treatment, drug, or medication. Do not disregard, avoid, or delay seeking medical advice from your physician (or other qualified healthcare professional) based on any information you may have received or obtained through the Site.

Healthcare professionals or public must not, under any circumstances, provide or publish any personal information (including but not limited to the name) of any individuals on the Site.

Each physician (or another qualified healthcare professional) is responsible for his professional services and compliance with the requirements applicable to his profession and license. We will not be liable for any professional advice or healthcare services you obtain from a physician (or another qualified healthcare professional) through his use of the Site.

We disclaim all responsibility if a physician (or another qualified healthcare professional) shares a patient support program with third parties who are not healthcare professionals.